Lurbinectedin is a chemotherapy drug used to treat small cell lung cancer (SCLC) and other solid tumors. In terms of toxicity, it has been found to have a manageable safety profile compared to other chemotherapy drugs. [1]

According to a study published in the Journal of Clinical Medicine, the most common side effects of lurbinectedin were fatigue, nausea, vomiting, and decreased appetite. [2] The study also reported that the incidence of severe adverse events was low, with only 4.4% of patients experiencing grade 3 or 4 toxicity.

Compared to other chemotherapy drugs, lurbinectedin has shown a lower incidence of pulmonary toxicity. Pulmonary toxicity is a common side effect of chemotherapy that can lead to lung damage and respiratory failure. [3] According to a review article in UpToDate, some chemotherapy drugs, such as bleomycin and gemcitabine, have a high risk of pulmonary toxicity. However, lurbinectedin has not been associated with significant pulmonary toxicity in clinical trials. [3]

In conclusion, lurbinectedin has a manageable safety profile compared to other chemotherapy drugs. The most common side effects are mild and the incidence of severe adverse events is low. Additionally, lurbinectedin has shown a lower incidence of pulmonary toxicity compared to other chemotherapy drugs. However, as with all chemotherapy drugs, patients should be monitored closely for potential side effects. [1][2][3]

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/
[3] https://www.uptodate.com/contents/pulmonary-toxicity-associated-with-antineoplastic-therapy-cytotoxic-agents